Skip to content

FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease

FitMi AD: a Safe and Motivating Computer-guided Exercise System for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05504811
Enrollment
31
Registered
2022-08-17
Start date
2023-09-08
Completion date
2025-03-12
Last updated
2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Dementia, Mild

Brief summary

This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. FitMi AD uses embedded sensors that can track and record the patient's direction and degree of movement while performing exercises described on a computer.

Interventions

DEVICEFitMi AD

Exercise using the motion sensing devices and a tablet computer

Exercise following printed sheets or booklet

Sponsors

Rancho Research Institute, Inc.
CollaboratorOTHER
Flint Rehabilitation Devices, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Single (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* have MCI or mild dementia due to AD (i.e. Clinical Dementia Rating (CDR) score 1 for mild dementia or 0.5 for MCI) * ability to clearly see the screen and hear the audio instructions from the tablet * have a family member or friend who can answer questions about the participant's daily living skills * willing to participate in a research study.

Exclusion criteria

* age \< 50 years old * use of a wheelchair as a primary mobility device (use of a cane or walker is permitted) * presence of other neurologic conditions such as movement disorders or history of stroke * other severe concurrent medical conditions that may prevent the participants from completing the 3-month study

Design outcomes

Primary

MeasureTime frameDescription
Change in Functional Reach TestBaseline, Immediately Post-Treatment (an average of 3 months)How far can someone reach while standing in a fixed position
Change in Timed Up and Go testBaseline, Immediately Post-Treatment (an average of 3 months)Time it takes to stand up from a chair and walk a short distance
Change in 30 second chair stand testBaseline, Immediately Post-Treatment (an average of 3 months)How many times someone stand up from a chair in 30 seconds

Secondary

MeasureTime frameDescription
Pittsburgh Sleep Quality IndexBaseline, Immediately Post-Treatment (an average of 3 months)Measures the quality and patterns of sleep in adults. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.
Visual Analog Pain ScaleBaseline, Immediately Post-Treatment (an average of 3 months)Indicates perceived pain intensity. The scale consists of a line, often 10 cm long, with verbal anchors at either end (i.e. no pain on the far left and the most intense pain imaginable on the far right). The patient places a mark at a point on the line corresponding to the patient's rating of pain intensity.
Duration of exercise performedImmediately Post-Treatment (an average of 3 months)Duration of exercise performed over intervention period.
Global Physical Activity QuestionnaireBaseline, Immediately Post-Treatment (an average of 3 months)Assesses physical activity habits
Geriatric Depression ScaleBaseline, Immediately Post-Treatment (an average of 3 months)Evaluates depression in elderly individuals. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026